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OBJECTIVES: The etiology of osteoporosis in asthma is complex as various factors contribute to its pathogenesis. The purpose 
of our study was to investigate the effects of obesity and inhaled steroids, as well as the severity and duration of asthma, on osteo-
porosis in postmenopausal asthma patients as compared to healthy controls. 
METHODS: A total of 46 patients with asthma and 60 healthy female controls, all postmenopausal, were enrolled in our study. 
Bone mineral density was assessed at the lumbar spine and hip using a Lunar DPX-L densitometer. 
RESULTS: Bone mineral density (BMD) scores were comparable between the asthmatic and control groups, with average scores 
of 0.95 ± 0.29 and 0.88 ± 0.14 g/cm2, respectively. Likewise, osteoporosis was diagnosed in a similar percentage of patients in the 
asthmatic (39.1%) and control (43.3%) groups. Bone fracture was identified in four patients with asthma (8.6%) and in six patients 
from the control group (10%). We could not detect any relationship between BMD and duration of asthma, asthma severity, inhaled 
steroids or body mass index (BMI). There was no difference between the two groups with respect to age or years since menopause. 
Although asthma patients were more likely to be overweight and presented higher BMD scores on average than the control subjects, 
these differences were not statistically significant. 
CONCLUSIONS: There is a slight positive protective effect of high BMI against osteoporosis in asthma patients, but this effect is 
overcome by time and menopause status. Therefore, the protective effect of obesity against osteoporosis in asthma patients seems 
to not be significant.
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INTRODUCTION
Osteoporosis is a systemic skeletal disease that leads to 
an increased risk of fracture as a result of a reduction in the 
amount of normally mineralized bone and deterioration in the 
microarchitectural bone tissue and trabecular elements. Bone 
mineral density (BMD) is the major measurable determinant 
of the risk for osteoporotic fracture.1 Obesity has a protective 
effect on bone metabolism while menopause is associated 
with a negative imbalance in bone metabolism.2,3 
Asthma is a chronic inflammatory disease of the 
airways with an estimated 300 million cases worldwide 
and is a significant cause of morbidity that is associated 
with reduced quality of life. Inhaled corticosteroids (ICS) 
are the most effective anti-inflammatory medication for 
the treatment of persistent asthma, with fewer side effects 
than oral corticosteroids. Although the increasing use of 
moderate and high doses of ICS over the long term has 
the potential to cause systemic side effects by suppression 314
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of the hypothalamic-pituitary–adrenal axis, regular use of 
inhaled steroids reduces the need for oral steroid therapy4. 
Both Egan5 and Kaye6 found that taking ICS for more than 
24 months had no significant effect on BMD. On the other 
hand, McDonalds7 and Israel8 showed that ICS usage can 
lead to bone loss. In most studies, confounding factors such 
as age, menopausal status, physical activity, body weight and 
BMI were not adequately taken into account. The effects of 
ICS on bone mineral density are therefore not clear and the 
appropriateness of this treatment regimen for osteoporotic 
asthmatic patients remains questionable. 
Coexistent osteoporosis was found to be a significant 
factor in negatively impacting the quality of life of asthma 
sufferers.9 Additionally, thoracic vertebral fractures can 
cause further impairment to lung function and Kado10 
reported increased mortality in elderly women with vertebral 
fractures. Osteoporosis is thus a very important consideration 
for asthma patients. 
The relationship between obesity and asthma has been 
widely studied and epidemiological evidence shows that the 
prevalence of each condition is increasing worldwide. The 
purpose of our study was to determine the effects of inhaled 
steroids and obesity, as well as asthma duration and severity, 
on osteoporosis in postmenopausal asthma patients. 
MATERIALS AND METHODS
Subjects
A total of 46 patients who presented with asthma as 
defined by GINA (The Global Initiative for Asthma)11 criteria 
were enrolled in this study from the pulmonology outpatient 
clinic at our facility. All patients were postmenopausal. 
Respiratory symptoms, medications and years since 
menopause were assessed in detail and pulmonary function 
tests were performed in a standard fashion using an 
electronic spirometer (MIR) for every subject. Each patient 
had to complete at least three forced vital capacity (FVC) 
maneuvers, the best of which was selected as directed by 
the European Respiratory Society. According to the results 
of the spirometer test, clinical asthma symptomatology 
and usage of medications, especially doses of inhaled 
corticosteroids, asthma patients were classified into three 
groups of increasing asthma severity according to GINA. 
Patient characteristics such as duration of asthma and ICS 
details (type of drugs, prescribed doses, compliance as 
estimated from questionnaire data, duration, and number of 
short courses of systemic steroids) were recorded. The ICS 
medications used by our cohort included beclametasone 
dipropionate (BDP), fluticasone proprionate (FP) or 
budesonide. The duration of use of each type of steroid 
inhaler as well as the mean daily and cumulative doses were 
determined from the patients’ medical diaries and expressed 
in terms of the equipotent dose of BDP in micrograms (µg) 
by a respiratory medicine specialist. Patients who had a 
history of continuous systemic corticosteroid use for more 
than one week during recent years were excluded from our 
study. Only those patients who had regularly taken ICS for 
at least 12 months were included in our study. 
A total of 60 healthy female postmenopausal subjects were 
enrolled in this study as a control group. All of the subjects 
were asked in detail about their asthma and pulmonary 
function tests were performed in ambiguous cases. Exclusion 
criteria for the study included a history of hypothyroidism, 
hyperthyroidism, diabetes, use of drugs that affect bone 
metabolism, and any other endocrine or inflammatory diseases 
that can affect body weight or bone metabolism. The daily 
physical activity and dietary habits of each patient were 
recorded. A validated food frequency questionnaire (FFQ)12 
containing 15 items that identifies the frequencies and portion 
sizes of consumed common food items in order to estimate 
daily calcium intake was completed by all patients. Only those 
who consumed 500-750 mg calcium daily were included in 
the study. Patients taking calcium supplements, osteoporosis 
medicine or any other medication likely to affect skeletal 
metabolism, such as sexual steroids, anticoagulants and 
anticonvulsive drugs, were not included in the study. 
Body mass index
Each participant’s height and weight were measured by 
the same individual using the same equipment. Weight was 
measured using a calibrated hospital scale with subjects 
dressed in normal indoor clothing but without wearing 
shoes. Height was measured in centimeters using a fixed tape 
measure with subjects standing shoeless on a hard surface 
against a wall. Body mass index was calculated by dividing 
body weight by height squared (kg/m2). Patients were 
evaluated in three groups according to their BMI: BMI ≤ 25 
(normal, group 1), BMI between 25.1 and 29.9 (overweight, 
group 2) and BMI ≥ 30 (obese, group 3).
Bone densitometry
Bone mineral density (g/cm2) was assessed by dual 
energy X-ray absorptiometry at the lumbar spine and 
hip (femoral neck and trochanter) using a Lunar DPX-L 
densitometer (Lunar Radiation; Madison WI). BMD is 
expressed as the standard deviation (SD) of means, T-score 
and Z-score. The Z-score is a SD from age- and sex-adjusted 
average BMD and the T- score is a SD from a young adult 
sex-matched control population. All scans were analyzed 315
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by the same doctor. The coefficient of variation was 0.5% 
with Phanton and 2% for the in vivo evaluation. Accuracy 
and precision were 1% and 2%, respectively. Osteoporosis 
was diagnosed according to the criteria of the World Health 
Organization (WHO) as a BMD of > 2.5 SD units below 
the mean for young adults. Osteopenia is in turn defined as 
a BMD between 1 and 2.5 SD units below the mean BMD 
for young adults (i.e., the T-score).13 All patients were asked 
to provide a history of doctor-diagnosed bone fractures 
(especially hip and vertebral breakages). Fractures with 
relevant clinical symptoms as well as those that occurred as 
a result of minor trauma were included. Fractures following 
severe trauma, like falling from greater than standing height 
or a traffic accident, were excluded.
Statistics
All results were expressed as means ± SD. The 
significance of differences between groups was assessed 
using the unpaired Student’s t-test or Mann Whitney U tests 
for continuous variables. The chi-square test or Fischer’s 
Exact test was used to test prevalence between groups. 
Pearson simple linear regression and correlation analyses 
were used to evaluate the interrelationships between 
parameters. In addition, regression analysis was used 
to assess the association between bone density and age, 
body mass, years since menopause, and asthma severity. 
The statistical analysis was performed using the SPSS-11 
program and p values < 0.05 were considered significant.
RESULTS 
A total of 46 patients presenting asthma as described by 
GINA and 60 healthy female controls, all postmenopausal, 
were enrolled in this study. There was no difference between 
the two groups with regard to age, race, smoking habits or 
years since menopause (Table 1). No patients were taking 
any medication for osteoporosis. All patients had a normal 
daily dietary calcium intake and all consumed similar 
amounts of milk and milk products according to their food 
frequency questionnaires (673.7 mg vs. 684.5 mg calcium 
daily for asthma and control groups, respectively). Although 
none of the women had regular exercise routines, they all 
maintained fully ambulatory, independent, active life-styles 
tailored to their jobs and daily activities. Although asthma 
patients were more likely to be overweight or obese, this 
difference was not statistically significant.
Among 42 of the asthma patients, 21 used budesonide, 
17 used FP and the others were on BDP. Characteristics of 
asthma patients, severity classifications according to GINA 
and details of ICS medication are shown in Table 2. 
Although we found that mean and total T- and Z-scores 
for both lumbar and femoral regions were lower in control 
subjects, this difference was not statistically significant. 
According to the WHO osteoporosis classifications for 
both lumbar and femoral T-scores, there was no difference 
between the groups (Table 3). The prevalence rate of bone 
fracture history was similar between groups. Three patients 
in the control group had a history of major traumatic 
vertebral fracture. Atraumatic vertebral fracture was recorded 
in four patients with asthma (8.6%) and in six patients from 
the control group (10%). None of the subjects reported hip 
fractures. 
The Pearson’s correlation analysis revealed no significant 
correlation between BMD and BMI, weight, duration of 
asthma, lung function, age, and asthma severity or inhaled 
steroid usage. As asthma severity increased from the mild to 
the severe form, mean lumbar T-scores decreased, but this 
Table 1 -  Demographic characteristics of patients in this 
study
Asthma Control p
Age (years) 62.5 ± 10.6 63.0 ± 6.1 0.561
Years since menopause 5.6 ± 1.2 6.5 ± 1.9 0.198
Race, gender White, females White, females
Body mass index
     Height (cm)
     Weight (kg)
28.4 ± 5.1
155.5 ± 3.59
69.2 ± 7.2
26.4 ± 4.6
158.0 ± 4.3
67.3 ± 7.7
0.078
0.037
0.465
BMI n (%)
     Normal
     Overweight
     Obese
9 (19.6)
23 (50)
14 (30.4)
21 (35)
22 (36.7)
17 (28.3)
0.677
Smoking Habits n (%)
     Current smoker
     Never smoked
     Quit smoking
4 (8.7)
36 (78.3)
6 (13)
6 (10)
48 (80)
6 (10)
0.356
BMI: Bone mineral index
Table 2 - Asthma-related parameters and pulmonary function 
test values for asthma patients
Variables Bronchial Asthma
Asthma severity (%)
   Mild
   Moderate
   Severe
42.6
33.4
22.5
Duration of asthma (years) 7.8 ± 7.7
FEV1  (mL) 2017.2 ± 618.1
FEV1 (% predicted) 83.1 ± 17.8
Duration of ICS (years) 4.3 ± 2.6
Cumulative ICS dose (mg)
Daily ICS dose (µg)
798.3 ± 348.1
324.9  ± 121.8
*Prescribed dose= equivalent dose of beclamethasone  × estimated compli-
ance316
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was not significant. For asthma patients, mean body weights 
were 65.2, 68.6 and 73.5 kg for osteoporotic, osteopenic 
and normal patients, respectively. Although we found a 
progressive parallel increase in mean body weights and 
lumbar T-scores, this trend was not statistically significant 
(Table 4). When the effect of age, years after menopause 
and BMI were adjusted in the logistic regression analysis, 
the risk of low BMD was found to be similar to that of the 
control group. 
DISCUSSION
The present study found no relationship between BMD 
and duration of asthma, lung function, age, asthma severity, 
use of inhaled steroids or body mass index. A progressive 
parallel increase in mean body weights and BMD scores 
was detected, but the relationship was not statistically 
significant. 
The etiology of osteoporosis in obstructive lung diseases 
is complicated by the fact that various factors contribute 
to its pathogenesis. Smoking, hypercapnia, chronic 
inflammation, reduced skeletal muscle mass and changes 
in body composition can all increase the risk of both 
osteoporosis and lung disorders. Altered lung function can 
induce limitations in physical activity due to dyspnoea.14,15 
Sin16 found that the risk of osteoporosis among males 
and females was positively correlated with the severity of 
obstructive disease. Katsura17 found that this relationship 
is more obvious in chronic bronchitis and emphysema 
patients than in asthmatics. It is unclear whether asthma 
alone is a risk factor for osteoporosis. Laatikainen18 showed 
that BMD scores of premenopausal asthmatics with no 
history of corticosteroid use did not differ from those of 
non-asthmatics. Similarly, in our study we did not find a 
relationship between asthma-related parameters and BMD, 
even after controlling for the use of ICS. Most of our patients 
had mild or moderate persistent asthma and recorded normal 
scores on the pulmonary function test, suggesting that they 
suffered no limitations in terms of physical activity. Most of 
our asthma and control patients denied smoking, while all 
others had a smoking history of fewer than ten packs/year. 
The effect of smoking was therefore also negligible. 
Obesity has been implicated as an asthma risk factor and 
has a positive effect on BMD. A meta analysis of prospective 
epidemiologic studies showed a dose response effect of 
elevated BMI on asthma incidence for both women and men, 
with an odds ratio of 1.92, 95%CI 1.43-2.59, p<0.0001.19 
The positive effect of obesity on bone is multifactorial. 
Estrogen levels tend to be higher in obese people due to 
the increased aromatization of testosterone to estrogen in 
adipose tissue, decreased sex hormone binding globulin 
that leads to an increase in free sex steroids, increased level 
of leptin in serum and increased synthesis of insulin-like 
growth factors in liver and in the skeleton, which each 
stimulate bone formation.20-21 Additionally, the mechanical 
impact of higher weight-bearing loads has a positive effect 
on bone mass, with the result that subjects with high BMIs 
tend to have higher BMD. In our study, we also found that 
obesity was more common among asthma patients and that 
mean body weights and BMD scores increased in parallel, 
but without statistical significance. We concluded that the 
protective effect of obesity probably decreases over time 
and with menopause status, which indicates that the effect of 
obesity on osteoporosis in postmenopausal asthma patients 
is likely not significant. 
ICS have become a key element in the treatment of 
asthma. These drugs are absorbed through mucosal surfaces 
into the systemic circulation, but the extent to which they 
have adverse effects on bone is uncertain. Herrala22 found 
that inhaling 1000 µg doses of BDP/day for a one-year 
period did not affect BMD. A cross-sectional study in 
postmenopausal women noted no difference in BMD on 
Table 3 - Bone mineral densitometer results and osteoporosis 
classifications
Bone data Asthma Control p
Lumbar T score -1.7 ± 1.3 -1.91 ±  1.1 0.190
Femoral T score -1.2 ± 1.2 -1.47 ±  0.9 0.173
Total Spine BMD, g/cm2 0.95 ± 0.29 0.88 ± 0.14 0.086
Femoral neck BMD, g/cm2 0.83 ± 0.12  0.74 ± 0.23 0.034
BMD Classification*  (n)
   Normal
   Osteopenia
   Osteoporosis
9
19
18
8
26
26
0.057
*Diagnosis of osteopenia and osteoporosis was performed according to 
T-score values. All values are presented as mean ± SD, all p values >0.05
Table 4 - Relationship between asthma severity, ICS and 
BMD
Lumbar spine
T-score
Femoral neck 
T-score
p
Asthma patients BMI
    Normal
    Overweight
    Obese
-1.8  ± 0.9
-1.7 ± 1.1
-1.0 ±1.4
-1.6 ± 0.8
-0.8 ± 1.1
-0.7± 1.1
0.786
Asthma severity
    Mild
    Moderate
    Severe
-1.9 ± 0.8
-0.9 ± 1.3
-1.5 ± 1.4
-1.2 ± 1.0
-0.6 ± 1.1
-1.2 ± 1.2
0.198
Mean daily dose of inhaled 
steroids  
    >500
    ≤500
-1.4 ± 0.9
-1.7 ± 1.2
-1.1± 0.7
-1.3±0.9
0.678317
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account of cumulative dose of ICS, duration or current 
dose greater than or less than 1000 µg.23 On the other 
hand, Wong24 identified a negative correlation between 
total cumulative dose of ICS and BMD and Hanania25 
concluded that ICS may affect bone density in a dose-
related fashion. The discrepancy between these results 
might be explained by confounding factors such as age, 
menopausal status, physical activity, body weight and BMI. 
Fujita26 found that in contrast to premenopausal asthmatic 
patients, postmenopausal asthmatics presented reduced 
BMD and decreased bone formation as a consequence 
of BDP treatment, and concluded that ovarian hormones 
may be protective against the adverse effects of ICS in 
the premenopausal stage. Although effects of confounding 
factors cannot be entirely excluded in a cross-sectional 
study, we searched for a relation between inhaled steroid 
dose and duration and BMD using linear regression analysis, 
accounting for potential confounders such as weight, BMI, 
exercise, oral steroid use, age and postmenopausal status. 
Our findings are in agreement with previous data suggesting 
that inhaled steroid therapy has no detrimental effect on 
bone density in postmenopausal asthmatic patients. In our 
study, the prevalence of osteoporosis and osteopenia was 
also similar between the asthma and control groups. ICS 
therapy allows patients to control their asthma and thus be 
able to exercise, which in turn improves BMD and protects 
against osteoporosis. Another advantage of inhaled steroids 
is that they reduce the need for oral corticosteroids by 
improving respiratory function. One potential limitation of 
our study is that we could not analyze biochemical markers 
of bone metabolism. These markers, however, have poor 
reproducibility and seem to be less sensitive for detecting 
changes than BMD.27 In addition, the correlation between 
laboratory tests and clinical adverse effects is at times 
negligible, so we preferred to rely upon bone densitometer 
findings.28 
Early detection of osteoporosis and therapeutic options 
for the prevention and management of osteoporosis are 
especially important for the female postmenopausal 
population. We found that BMD values of postmenopausal 
asthma patients were no different from those of control 
subjects of the same age group who exhibited similar 
characteristics in terms of other parameters. We conclude that 
the risk of osteoporosis does not increase for appropriately 
treated asthma patients and that there is a slight positive 
protective effect of high BMI against osteoporosis in asthma 
patients. However, this effect is rendered insignificant by age 
and years of estradiol deficiency.
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